Ocular Gene Therapy with Adeno-associated Virus Vectors: Current Outlook for Patients and Researchers
In this “Perspective”, we discuss ocular gene therapy – the patient's perspective, the various strategies of gene replacement and gene editing, the place of adeno-associated virus vectors, routes of delivery to the eye and the remaining question - “why does immunity continue to limit efficacy?”...
Main Authors: | Geoffrey A. Casey, Kimberly M. Papp, Ian M. MacDonald |
---|---|
Format: | Article |
Language: | English |
Published: |
Knowledge E
2020-08-01
|
Series: | Journal of Ophthalmic & Vision Research |
Online Access: | https://doi.org/10.18502/jovr.v15i3.7457 |
Similar Items
-
The Therapeutic Application of Ocular Disease with Recombinant Adeno-Associated Virus Vector
by: Ming-Ling Tsai, et al.
Published: (2001) -
The state of the art of adeno-associated virus-based vectors in gene therapy
by: Nardi Nance, et al.
Published: (2007-10-01) -
Correction: The state of the art of adeno-associated virus-based vectors in gene therapy
by: Nardi Nance, et al.
Published: (2010-01-01) -
Gene Therapy for Retinal Diseases by Use of Recombinant Adeno-Associated Virus Vector
by: Mong-Ping Shyong, et al.
Published: (2009) -
Cellular Immunity in Recombinant Adeno-Associated Virus Vector Mediated Gene Therapy
by: Xu, Dan
Published: (2011)